Diagnostic features of initial demyelinating events associated with serum MOG-IgG
Copyright © 2020 Elsevier B.V. All rights reserved..
BACKGROUND: Myelin oligodendrocyte glycoprotein (MOG)-IgG associated disorders are increasingly recognized as a distinct disease entity. However, diagnostic sensitivity and specificity of serum MOG-IgG as well as recommendations for testing are still debated.
MATERIALS AND METHODS: Between October 2015 and July 2017 we tested serum MOG-IgG in 91 adult patients (49 females) with a demyelinating event (DE) not fulfilling 2010 McDonald criteria for MS at sampling, negative for neuromyelitis optica (NMO)-IgG and followed-up for at least 12 months. We assessed the sensitivity and specificity of a live-cell MOG-IgG assay for each final diagnosis at last follow-up, for the 2018 international recommendations for MOG-IgG testing, and for other combinations of clinical and laboratory characteristics.
RESULTS: Clinical presentations included acute myelitis (n = 48), optic neuritis (n = 36), multifocal encephalomyelitis (n = 4), and brainstem syndrome (n = 3). Twenty-four patients were MOG-IgG positive. Sensitivity and specificity of MOG-IgG test applied to the 2018 international recommendations were 28.4% and 86.7%, while they were 42.1% and 88.6% when applied to DE of unclear aetiology as defined above with two or more among: 1_no periventricular and juxtacortical MS-like lesions on brain MRI; 2_longitudinally extensive MRI optic nerve lesion; 3_no CSF-restricted oligoclonal bands; 4_CSF protein > 50 mg/dl.
CONCLUSIONS: Simplified requirements compared to those currently proposed for MOG-IgG testing could facilitate the applicability of the assay in the diagnosis of adults with DEs of unclear aetiology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:344 |
|---|---|
| Enthalten in: |
Journal of neuroimmunology - 344(2020) vom: 15. Juli, Seite 577260 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Orlandi, Riccardo [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.11.2020 Date Revised 11.11.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jneuroim.2020.577260 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310250994 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310250994 | ||
| 003 | DE-627 | ||
| 005 | 20231225135705.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jneuroim.2020.577260 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1034.xml |
| 035 | |a (DE-627)NLM310250994 | ||
| 035 | |a (NLM)32442864 | ||
| 035 | |a (PII)S0165-5728(20)30222-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Orlandi, Riccardo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diagnostic features of initial demyelinating events associated with serum MOG-IgG |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.11.2020 | ||
| 500 | |a Date Revised 11.11.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: Myelin oligodendrocyte glycoprotein (MOG)-IgG associated disorders are increasingly recognized as a distinct disease entity. However, diagnostic sensitivity and specificity of serum MOG-IgG as well as recommendations for testing are still debated | ||
| 520 | |a MATERIALS AND METHODS: Between October 2015 and July 2017 we tested serum MOG-IgG in 91 adult patients (49 females) with a demyelinating event (DE) not fulfilling 2010 McDonald criteria for MS at sampling, negative for neuromyelitis optica (NMO)-IgG and followed-up for at least 12 months. We assessed the sensitivity and specificity of a live-cell MOG-IgG assay for each final diagnosis at last follow-up, for the 2018 international recommendations for MOG-IgG testing, and for other combinations of clinical and laboratory characteristics | ||
| 520 | |a RESULTS: Clinical presentations included acute myelitis (n = 48), optic neuritis (n = 36), multifocal encephalomyelitis (n = 4), and brainstem syndrome (n = 3). Twenty-four patients were MOG-IgG positive. Sensitivity and specificity of MOG-IgG test applied to the 2018 international recommendations were 28.4% and 86.7%, while they were 42.1% and 88.6% when applied to DE of unclear aetiology as defined above with two or more among: 1_no periventricular and juxtacortical MS-like lesions on brain MRI; 2_longitudinally extensive MRI optic nerve lesion; 3_no CSF-restricted oligoclonal bands; 4_CSF protein > 50 mg/dl | ||
| 520 | |a CONCLUSIONS: Simplified requirements compared to those currently proposed for MOG-IgG testing could facilitate the applicability of the assay in the diagnosis of adults with DEs of unclear aetiology | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Autoimmune diseases of the nervous system | |
| 650 | 4 | |a Epidemiology | |
| 650 | 4 | |a Immunology | |
| 650 | 4 | |a MOG | |
| 650 | 4 | |a Multiple sclerosis | |
| 650 | 4 | |a Neuromyelitis optica | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Myelin-Oligodendrocyte Glycoprotein |2 NLM | |
| 700 | 1 | |a Mariotto, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrari, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Gobbin, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Sechi, Elia |e verfasserin |4 aut | |
| 700 | 1 | |a Capra, Ruggero |e verfasserin |4 aut | |
| 700 | 1 | |a Mancinelli, Chiara Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Bombardi, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Zuliani, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Zoccarato, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Rossi, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Camera, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Ferraro, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Benedetti, Maria Donata |e verfasserin |4 aut | |
| 700 | 1 | |a Reindl, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Gajofatto, Alberto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neuroimmunology |d 1985 |g 344(2020) vom: 15. Juli, Seite 577260 |w (DE-627)NLM012614181 |x 1872-8421 |7 nnns |
| 773 | 1 | 8 | |g volume:344 |g year:2020 |g day:15 |g month:07 |g pages:577260 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jneuroim.2020.577260 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 344 |j 2020 |b 15 |c 07 |h 577260 | ||